Medicated feed premix manufacture begins with geometric dilution of Sulfamethoxazole veterinary grade API into ground corn cob or lactose monohydrate. Active loading is commonly 10% w/w SMZ with 2% w/w trimethoprim to maintain the 5:1 ratio. A ribbon blender with 1000 L working volume is charged at 60–70% fill. The API is pre-blended with 2.0% w/w colloidal silicon dioxide before addition to reduce electrostatic agglomeration. Blending proceeds at 12 rpm for 20 min. Sampling is performed at 10 points using a thief sampler. Acceptance requires assay RSD ≤ 5.0%. The premix is passed through a 0.71 mm screen to remove soft aggregates. Moisture content is maintained below 5.0% at release because higher water activity accelerates sulfonamide hydrolysis. The finished premix is packaged in multi-wall paper bags with polyethylene liner. Cross-contamination control follows 21 CFR 225.1; rinse and swab samples are assayed by HPLC-UV at 254 nm. Carryover of SMZ into non-medicated feed must not exceed 10 ppm unless a validated cleaning limit justifies a higher value.

What Limits Direct Compression of SMZ Tablets Above 600 mg Unit Mass?

Veterinary tablets containing 400 mg SMZ and 80 mg trimethoprim produce a core mass near 480 mg; bolus tablets can exceed 1,000 mg. Direct compression is constrained by poor flow of ungranulated SMZ powder. Bulk density is typically 0.35–0.45 g/cm³; Carr index exceeds 30%. Wet granulation is therefore specified for tablet manufacture. A high-shear mixer granulator with a 25 L bowl is charged with SMZ, trimethoprim, microcrystalline cellulose at 20% w/w, and croscarmellose sodium at 4.0% w/w. Binder solution contains povidone K30 at 5.0% w/v in purified water. Impeller speed is set at 200 rpm; chopper speed is set at 1,500 rpm. Granulation end-point is reached when impeller power draw reaches 40–60% of motor capacity and granulate appears as coarse, irregular agglomerates. The wet mass is dried in a fluid-bed dryer at inlet air 60 °C until loss on drying falls to 2.0–3.0%. The dried granulate is milled through a 1.0 mm screen. Magnesium stearate is added at 0.50% w/w and blended for 5 min. Tablets are compressed on a rotary tablet press with 12–18 kN main compression force. Crushing strength is controlled between 60 N and 90 N. Friability is maintained below 0.8% per USP <1216>. Disintegration time must not exceed 15 min per USP <701>. Dissolution is tested using USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer at 37 °C; the acceptance criterion is taken from the approved veterinary monograph. Film coating is applied when products are packaged in light-exposed blister strips. A 3.0–4.0% weight gain of hydroxypropyl methylcellulose-based coating is applied in a perforated pan coater at 45 °C bed temperature. Granulation fluids above pH 9.0 dissolve the free acid and slow blending; alkaline binder systems are avoided unless SMZ is converted to the sodium salt before wet massing.

Water-Soluble Powder, pH 9.5–10.5, and Hard Water Precipitation Boundaries

Water-soluble powder containing SMZ at 20% w/w and trimethoprim at 4% w/w is prepared as a buffered alkaline product. Free sulfamethoxazole is practically insoluble below pH 6.0. The sodium salt or in-situ salt formation using anhydrous sodium carbonate is required for reconstitution. A typical powder blend contains SMZ at 20% w/w, trimethoprim at 4% w/w, sodium carbonate at 25–35% w/w, sodium citrate at 10–15% w/w, lactose monohydrate at 25–30% w/w, and colloidal silicon dioxide at 1.0% w/w. The powder is dry-blended in a V-blender for 30 min at 60% fill. Stock solution is prepared at 1:25 dilution in potable water. Final pH should be 9.5–10.5 to keep SMZ in solution as the sodium salt. Hard water with total hardness above 250 mg/L as CaCO₃ can induce precipitation of sulfamethoxazole as the poorly soluble free acid or insoluble carbonate complexes. Lines and nipple drinkers must be flushed after use; precipitation is observed when stock solution is left standing for more than 8 h at low ambient pH. The product is not compatible with acidifiers such as citric acid concentrates because pH drops below 8.0 and SMZ crystallises. Dissolution check is performed in a 100 mL volumetric flask test; if undissolved particles remain after 5 min of gentle swirling, the water source requires pre-treatment. Re-testing of hardness and alkalinity is required when field pharmacy water is sourced from bore wells or surface reservoirs with seasonal mineral load variation.

When Sulfamethoxazole Sodium Replaces Free Acid in Aseptic Filling

Injectable veterinary formulations use the sodium salt of sulfamethoxazole because SMZ free acid has water solubility below 1.0 mg/mL at 25 °C. Sulfamethoxazole sodium is dissolved in Water for Injection at a concentration equivalent to 200 mg/mL SMZ activity with 40 mg/mL trimethoprim. Trimethoprim is dissolved in a cosolvent system containing propylene glycol and lactic acid or hydrochloric acid. The two solutions are combined under pH control. Final pH is adjusted to 9.5–10.0 with 1.0 M sodium hydroxide. The solution is sterile-filtered through a 0.22 µm PVDF membrane under nitrogen pressure at 1.0–2.0 bar. Terminal sterilisation at 121 °C for 15 min is acceptable only if forced degradation data show no more than 0.5% total new impurities. Without such data, aseptic filtration is used. The solution must be protected from carbon dioxide; if not, carbonate salts form and pH drifts downward. Precipitation risk increases if the solution is diluted with saline below pH 8.5; therefore dilution before intravenous administration must be validated. Sterility testing follows USP <71>; bacterial endotoxin limit is established per USP <85>. Particulate matter is controlled under USP <788> for large-volume parenterals or USP <790> for visible particles. A 10 mL vial headspace oxygen content should be below 2.0% after nitrogen flushing. Residual solvent limits follow VICH GL18(R2). If propylene glycol is used above 40% v/v, viscosity rises above 5 cP at 20 °C, slowing sterile filtration. Filter compatibility must be tested because high pH can leach extractables from nylon membranes.

Capsule filling of SMZ/trimethoprim 200 mg/40 mg veterinary powders is performed on an automatic dosator capsule filler operating at 12,000 capsules/h. The fill formulation contains SMZ at 80.0% w/w, trimethoprim at 16.0% w/w, lactose monohydrate at 2.0% w/w, pregelatinised starch at 1.0% w/w, and magnesium stearate at 1.0% w/w. Powder blend moisture must not exceed 3.0% before encapsulation because SMZ particles adhere to dosator pins above this threshold. The blend is passed through a 0.5 mm screen to break agglomerates. Content uniformity is verified per USP <905>; acceptance value ≤ 15.0 is required. Dissolution is performed per USP <711> using Apparatus 1 at 100 rpm in 900 mL of pH 6.8 buffer. Capsules are packaged in PVC/PE/Alu blisters with desiccant if the product is intended for tropical markets. Gelatin capsules are avoided in feed top-dressing applications where capsules may be opened into feed; hypromellose capsules are used instead to prevent shell crosslinking with alkaline feed additives.

Power-Draw Plateau Detection in High-Shear Granulation of 200 mg/g Oral Paste Granules

Granulated SMZ for oral paste or top-dressing is prepared at 200 mg/g active strength with trimethoprim at 40 mg/g. The granulation is performed in a 50 L high-shear mixer. Binder solution is povidone K30 at 8.0% w/v in water. The impeller runs at 150 rpm; chopper runs at 1,000 rpm. End-point is identified by impeller power draw plateau. When power draw remains stable for 60 s within ±2%, binder addition stops. Over-wetting causes power draw to rise again and produces granules with particle size above 1.4 mm, which are unsuitable for syringe or oral paste administration. The wet granules are dried at 50 °C to loss on drying 2.0–4.0%. The dried granules are screened to a target fraction of 125–500 µm. Particles finer than 125 µm are recycled into the next granulation batch. The granules are blended with microcrystalline cellulose at 5.0% w/w and sodium starch glycolate at 2.0% w/w before packaging in sachets. A sachet containing 1 g granules delivers 200 mg SMZ. Dispensing instructions for horses or calves must avoid coadministration with oral acidifiers because sulfonamide crystalluria risk increases when urine pH falls below 5.5. The granule route is used when tablets cannot be administered to free-range livestock; the granules are mixed into a small amount of feed immediately before use.

Dry syrup for oral suspension containing 200 mg SMZ and 40 mg trimethoprim per 5 mL is filled as a powder into 100 mL HDPE bottles. The powder blend consists of SMZ at 40.0% w/w, trimethoprim at 8.0% w/w, sucrose at 45.0% w/w, sodium carboxymethylcellulose at 2.5% w/w, sodium citrate at 2.0% w/w, citric acid at 1.0% w/w, and flavouring at 1.5% w/w. Reconstitution is done by adding purified water to the mark; the suspension pH is 6.0–7.0. Sodium carboxymethylcellulose hydrates within 10 min to form a thixotropic gel. The suspension must be shaken before each administration because SMZ particles sediment. Sedimentation volume after 24 h should be ≥ 0.7. The suspension is stored at 25 °C for no more than 14 days after reconstitution; microbial challenge tests follow USP <51> for oral products. pH drift during storage is limited to ±0.5 units. If the product is used in calves, the label must include withdrawal time data generated under VICH GL3(R) stability protocols.